Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: diabetic retinopathy therapy - QuatRx Pharmaceuticals

Drug Profile

Research programme: diabetic retinopathy therapy - QuatRx Pharmaceuticals

Alternative Names: Diabetic retinopathy research programme - QuatRx Pharmaceuticals

Latest Information Update: 20 Dec 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hormos Medical; QuatRx Pharmaceuticals
  • Developer Hormos Medical
  • Class
  • Mechanism of Action Neuropeptide Y receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic retinopathy

Most Recent Events

  • 20 Dec 2005 Discontinued - Preclinical for Diabetic retinopathy in Finland (Intravitreous)
  • 16 Jun 2005 Hormos Medical has been acquired and merged into QuatRx Pharmaceuticals
  • 22 Jun 2004 The programme is available for licensing (http://www.hormos-med.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top